This product is a hypoglycemic drug that can reduce fasting and postprandial hyperglycemia in patients with type 2 diabetes, and can reduce HbAlc by 1% to 2%. Its mechanism of lowering blood sugar is: 1. Increase the sensitivity of peripheral tissues to insulin and increase insulin-mediated glucose utilization. 2. Increase the utilization of glucose by non-insulin-dependent tissues, such as the brain, blood cells, renal medulla, intestines, skin, etc. 3. Inhibit hepatic gluconeogenesis and reduce hepatic glucose output. 4. Inhibit intestinal wall cells from taking up glucose. Unlike the action of insulin, this product has no effect on promoting fat synthesis, has no obvious hypoglycemic effect on normal people, and generally does not cause hypoglycemia when used alone for type 2 diabetes.

This product is a hypoglycemic drug that can reduce fasting and postprandial hyperglycemia in patients with type 2 diabetes. Its mechanism includes increasing the sensitivity of peripheral tissues to insulin, increasing the utilization of glucose by non-insulin-dependent tissues, inhibiting hepatic gluconeogenesis and reducing hepatic glucose output, and inhibiting intestinal wall cells from taking up glucose. It has no effect on promoting fat synthesis and no obvious hypoglycemic effect on normal people. It generally does not cause hypoglycemia when used alone.

Regulate autonomic dysfunction and endocrine imbalance

This product is a quinolone antibacterial drug, which has strong antibacterial effect on Gram-negative bacteria, including Escherichia coli, Klebsiella pneumoniae, Proteus, Salmonella typhi, Salmonella paratyphi, Shigella, Enterobacter cloacae, Enterobacter aerogenes, Citrobacter, Serratia marcescens, Pseudomonas aeruginosa, Neisseria meningitidis, Haemophilus influenzae, Moracata, Legionella pneumophila, Neisseria gonorrhoeae, etc. It also has moderate antibacterial effect on Gram-positive cocci such as Staphylococcus and hemolytic Streptococcus. The mechanism of action of this product is to inhibit the bacterial DNA gyrase and thus kill bacteria.

This product is a macrolide antibiotic, which has inhibitory effects on Gram-positive bacteria such as Staphylococcus aureus, Streptococcus, and Pneumococcus, as well as some Gram-negative bacteria such as Haemophilus influenzae, Bordetella pertussis, Neisseria gonorrhoeae, Legionella pneumophila, and some anaerobic bacteria such as Bacteroides fragilis, Streptococcus peptostreptococcus, and Propionibacterium acnes. In addition, it also has inhibitory effects on mycoplasma. The characteristics of this product are that its antibacterial activity in vitro is similar to that of erythromycin, but its antibacterial activity in vivo against some bacteria such as Staphylococcus aureus, Streptococcus, and Haemophilus influenzae is stronger than that of erythromycin. There is cross-resistance between this product and erythromycin. The mechanism of action of this product is to inhibit the association of the 50S subunit of the nuclear protein and inhibit protein synthesis to produce an antibacterial effect.